Capmatinib Hydrochloride
Tier C — Watch / tradeCapmatinib Hydrochloride · all drugs expiring in 2032 →
Targets：c-Met
Brand：Tabrecta
Indications (approved)：Non-small cell lung cancer
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| CAPMA-001 | 153556-42-4Available | 4-bromo-3-fluorobenzoic acid |
| CAPMA-002 | 695188-21-7Available | 4-bromo-3-fluorobenzoyl chloride |
| CAPMA-003 | 343564-56-7Available | 4-bromo-3-fluoro-N-methoxy-N-methylbenzamide |
| CAPMA-004 | 304445-49-6Available | 1-(4-bromo-3-fluorophenyl)ethanone |
| CAPMA-005 | 1006875-89-3Available | 1-(4-bromo-3-fluorophenyl)-2,2-dihydroxyethanone |
| CAPMA-006 | 1029714-83-7Available | 2-(4-bromo-3-fluorophenyl)-2-oxoacetaldehyde |
| CAPMA-007 | 1006875-90-6Available | 1-(4-bromo-3-fluorophenyl)-2,2-diethoxyethanone |
| CAPMA-008 | 2200-97-7Available | - |
| CAPMA-009 | 1029714-84-8Available | 6-(4-bromo-3-fluorophenyl)-1,2,4-triazin-3-amine |
| CAPMA-010 | 1029714-85-9Available | 2-chloro-3-(quinolin-6-yl)propanal |
| CAPMA-011 | 1029714-86-0Available | 6-((2-(4-bromo-3-fluorophenyl)imidazo[1,2-b][1,2,4]triazin-7-yl)methyl)quinoline |
| CAPMA-012 | 1029714-87-1Available | 2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzonitrile |
| CAPMA-013 | 1029714-88-2Available | 2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzoic acid |
| CAPMA-014 | 5332-25-2Available | 6-bromoquinoline |
| CAPMA-015 | 476660-18-1Available | 3-(quinolin-6-yl)propanal |
| Capmatinib | 1029712-80-8Available | 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide |
Frequently asked questions
What are the approved indications of Capmatinib Hydrochloride?
Approved indications include: Non-small cell lung cancer.
When does the Capmatinib Hydrochloride patent expire?
Based on public sources, the Capmatinib Hydrochloride patent expires in 2032.
How many synthesis routes are recorded for Capmatinib Hydrochloride?
1 synthesis routes are recorded; the shortest is 12 steps with 260 mg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Capmatinib Hydrochloride intermediates?
16 intermediate CAS of Capmatinib Hydrochloride are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Capmatinib Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29